First Oral Drug for Moderate-To-Severe Ulcerative Colitis

被引：0
|
作者：
Aschenbrenner, Diane S.
机构：
来源：
AMERICAN JOURNAL OF NURSING | 2018年 / 118卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Immediate-release tofacitinib (Xeljanz) is now approved to treat moderate-to-severe ulcerative colitis. Nurses should assess patients for infections prior to the initiation of and throughout tofacitinib treatment.
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [31] First JAK Inhibitor approved for moderate to severe Ulcerative Colitis
    Fessler, Beate
    VISCERAL MEDICINE, 2018, 34 (05) : 398 - 398
  • [32] Treatment Patterns Among Patients With Moderate-to-Severe Ulcerative Colitis in the United States
    DiBonaventura, Marco
    Bargo, Danielle
    Lucas, James
    Bluff, Daniel
    Hoskin, Ben
    Salese, Leonardo
    Cappelleri, Joseph C.
    Quirk, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S353 - S353
  • [33] A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children
    Pigneur, Benedicte
    Ruemmele, Frank M.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (11-12) : 1023 - 1028
  • [34] Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis
    Lopes, Sara R.
    Martins, Claudio
    Teixeira, Madalena
    Tomas, David
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (34)
  • [35] Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Feagan, Brian G.
    Marano, Colleen
    Zhang, Hongyan
    Strauss, Richard
    Johanns, Jewel
    Adedokun, Omoniyi J.
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter R.
    Collins, Judith
    Jarnerot, Gunnar
    Rutgeerts, Paul
    GASTROENTEROLOGY, 2014, 146 (01) : 96 - +
  • [36] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal B.
    GASTROENTEROLOGY, 2012, 142 (02) : 257 - +
  • [37] An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis
    Rowan, Catherine
    Ungaro, Ryan
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (08) : 893 - 904
  • [38] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [39] Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities
    Ma, Christopher
    Choi, May Y.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (02): : 110 - 112
  • [40] Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Van Assche, Gert A.
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert R.
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal
    GASTROENTEROLOGY, 2011, 140 (05) : S123 - S124
12345